AstraZeneca bets $25M on preclinical bispecific against hot target, docking in Chinese Harbour to land global rights

AstraZeneca has joined the swarm of biotechs targeting Claudin18.2 (CLDN18.2). In return for $25 million upfront and more on the back end, the Big Pharma has landed worldwide rights to Harbour BioMed’s (HBM's) bispecific, positioning it to fight for a market targeted by Amgen, Astellas, BioNTech and more.